Teva’s management has expressed confidence in helping to resolve manufacturing issues at its US biosimilars partner Alvotech and has also hinted at new biosimilars deals on the horizon in the near future. However, at the same time the firm’s CEO acknowledged that the “bumpy” US market was still carrying a degree of uncertainty that is leading the firm to allocate capital accordingly.
During the firm’s third-quarter results presentation (see sidebar), president and CEO Richard Francis provided updates on Teva’s biosimilars interests, in...
